Related news
-
![]()
Sanofi adds mRNA to coronavirus vaccine push
Published: 27/03/2020A deal with Translate Bio to develop an mRNA-based vaccine adds the newer technology to the French pharma’s pandemic response. Read moreSource: www.biopharmadive.com -
-
![]()
For CAR-T, coronavirus brings uneven impact to studies, treatment
Published: 27/03/2020Cancer cell therapy, approved only for the very sick, depends on a complex and precisely timed series of steps, all of which could be disrupted by coronavirus' spread. Read moreSource: www.biopharmadive.com -
![]()
Despite another delay, Intercept says its NASH drug remains on track
Published: 26/03/2020The coronavirus outbreak, though, adds more uncertainty to what will be a closely watched regulatory review of Intercept's therapy. Read moreSource: www.biopharmadive.com
-
![]()
Bluebird says gene therapy application delayed again, citing disagreement with FDA
Published: 26/03/2020The biotech now expects to complete its FDA submission for LentiGlobin by mid next year, roughly a year past when it first expected to finish filing its application. Read moreSource: www.biopharmadive.com -
![]()
Bristol Myers investors breathe easier as multiple sclerosis drug approved by FDA
Published: 26/03/2020Regulatory clearance for Zeposia is the first of three drug approval milestones that must be met for former Celgene shareholders to see the full value of the 2019 acquisition. Read moreSource: www.biopharmadive.com -
![]()
In rare move, Gilead gives up 'orphan' status for experimental coronavirus drug
Published: 25/03/2020After sparking controversy, the biotech asked the FDA to rescind a designation designed to encourage research into therapies for rare diseases. Read moreSource: www.biopharmadive.com
-
![]()
China halts import of Bristol Myers cancer drug after inspection at US plant
Published: 25/03/2020Chinese drugmaker Beigene, which sells Bristol Myers' Abraxane in China, said it's bracing for a disruption in supply of the chemotherapy. Read moreSource: www.biopharmadive.com -
![]()
Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug
Published: 25/03/2020The Belgian drugmaker announced this week that a series of Phase 2 and Phase 3 studies for filgotinib, an immune system regulator, had paused enrollment because of safety concerns related to COVID-19. Read moreSource: www.biopharmadive.com -
![]()
AstraZeneca turns again to UK's Silence in renewed RNAi push
Published: 25/03/2020AstraZeneca and Silence Therapeutics, which first partnered in 2007, will team up to develop RNA interference drug candidates for diseases of the liver, heart, kidney and lung. Read moreSource: www.biopharmadive.com
-
![]()
Coronavirus forces ASCO, cancer research's top meeting, to move online
Published: 24/03/2020State governments, including ASCO's host state of Illinois, are calling for residents to stay home, making the prospect of holding a meeting that draws thousands untenable. Read moreSource: www.biopharmadive.com -
![]()
Novavax's positive flu data bring a stock bump and a spotlight on coronavirus vaccine
Published: 24/03/2020A large study found Nanoflu to be non-inferior to Sanofi's Fluzone. Safety results, meanwhile, will add to a database that Novavax said it will use to support its COVID-19 program. Read moreSource: www.biopharmadive.com -
![]()
COVID-19 and pharma's in-person sales model
Published: 24/03/2020Once the pharma industry and its customers learn to function in a world without face-to-face detailing, we may see the digital flip switch with physicians preferring to engage via digital channels. Read moreSource: www.biopharmadive.com
-
![]()
A guide to clinical trials disrupted by the coronavirus pandemic
Published: 23/03/2020As COVID-19 cases surge, drugmakers are halting studies of drugs for other diseases to limit patient risk and ease pressure on overwhelmed hospitals. Read moreSource: www.biopharmadive.com -
![]()
Leukemia drug from Roche, AbbVie extends survival, study finds
Published: 23/03/2020Paired with chemotherapy, Venclexta succeeded in a Phase 3 acute myeloid leukemia trial just weeks after falling short in another combination study. Read moreSource: www.biopharmadive.com -
![]()
Gilead, flooded with requests, suspends access to experimental coronavirus drug
Published: 23/03/2020The biotech plans to transition to an expanded access program for remdesivir, which is being tested as a treatment for COVID-19 in five late-stage studies. Read moreSource: www.biopharmadive.com
-
![]()
Lilly, Galapagos halt trials as coronavirus deepens impact on drug research
Published: 23/03/2020The moves likely herald similar announcements by other large drugmakers as medical centers focus resources on treating patients with COVID-19. Read moreSource: www.biopharmadive.com -
![]()
Drugmakers boost production of malaria pill touted by Trump as coronavirus treatment
Published: 20/03/2020Chloroquine, a decades-old generic therapy, has drawn attention as a potential therapy for COVID-19, although the evidence supporting its promise is thin. Read moreSource: www.biopharmadive.com -
![]()
Remdesivir, chloroquine move to forefront as White House tries to speed coronavirus response
Published: 19/03/2020Officials pointed to the expansion of compassionate use programs as a potential answer for U.S. coronavirus patients in urgent need of medical care. Read moreSource: www.biopharmadive.com
-
![]()
FDA scales back domestic inspections amid coronavirus outbreak
Published: 19/03/2020The agency's announcement comes a little over a week after it postponed nearly all overseas inspections, which are a critical oversight tool. Read moreSource: www.biopharmadive.com -
![]()
In hard-hit Seattle, coronavirus pushes biotechs to a new normal
Published: 19/03/2020Local drugmakers are on the frontlines of a pandemic that's affecting travel, clinical research and daily operations. It's forcing them to adapt quickly. Read moreSource: www.biopharmadive.com -
![]()
US automakers study medical manufacturing as coronavirus squeezes capacity
Published: 19/03/2020Switching to produce medical equipment will require new supply lines running to manufacturing facilities that are capable of delivering needed components. Read moreSource: www.biopharmadive.com